Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer

Francesca Ricci, Federica Guffanti, Roberta Affatato, Laura Brunelli, Pastorelli Roberta, Robert Fruscio, Patrizia Perego, Maria Rosa Bani, Giovanna Chiorino, Andrea Rinaldi, Francesco Bertoni, Maddalena Fratelli, Giovanna Damia

Research output: Contribution to journalArticlepeer-review


Mucinous ovarian carcinoma (mEOC) represents a rare subtype of epithelial ovarian cancer, accounting for 3-4% of all ovarian carcinomas. The rarity of this tumor type renders both the preclinical and clinical research compelling. Very few preclinical in vitro and in vivo models exist. We here report the molecular, metabolic and pharmacological characterization of two patient derived xenografts (PDXs) from mEOC, recently obtained in our laboratory. These PDXs maintain the histological and molecular characteristics of the patient's tumors they derived from, including a wild type TP53. Gene expression analysis and metabolomics profile suggest that they differ from high grade serous/endometrioid ovarian carcinoma PDXs. The pharmacological characterization was undertaken testing the in vivo antitumor activity of both cytotoxic agents (cisplatin, paclitaxel, yondelis, oxaliplatin and 5-fluorouracile) and targeted agents (bevacizumab and lapatinib). These newly established mucinous PDXs do recapitulate mEOC and will be of value in the preclinical development of possible new therapeutic strategies for this tumor type.

Original languageEnglish
Pages (from-to)572-580
Number of pages9
JournalAmerican Journal of Cancer Research
Issue number2
Publication statusPublished - 2020


Dive into the research topics of 'Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer'. Together they form a unique fingerprint.

Cite this